CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
Seung Hoon Beom, Jisu Oh, Tae-Yong Kim, Kyung-Hun Lee, Yaewon Yang, Koung Jin Suh, Hyeong-Gon Moon, Sae-Won Han, Do-Youn Oh, Wonshik Han, Tae-You Kim, Dong-Young Noh, Seock-Ah Im
Cancer Research and Treatment. 2017;49(2):454-463.   Published online 2016 August 23    DOI: https://doi.org/10.4143/crt.2016.259

Excel Download

417 POSTER Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
European Journal of Cancer Supplements. 2005;3(2):117   Crossref logo
Link1 Link2

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial
The Breast. 2012;21(1):27-33   Crossref logo
Link1 Link2

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting
Breast Cancer Research and Treatment. 2017;163(3):635-635   Crossref logo
Link1 Link2 Link3

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
Cancer Research and Treatment. 2017;49(2):454-463   Crossref logo
Link1 Link2 Link3

Cost-Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for Postmenopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Advanced/Metastatic Breast Cancer from A UK National Health Service Perspective
Value in Health. 2017;20(9):A433   Crossref logo
Link1 Link2

5048 A Q-TWiST analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR+) metastatic breast cancer (MBC)
European Journal of Cancer Supplements. 2009;7(2):275   Crossref logo
Link1 Link2

PR86 RETROSPECTIVE STUDY OF EVEROLIMUS WITH FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER PRETREATED WITH AROMATASE INHIBITORS(AI'S) AND SELECTIVE ESTROGEN MODIFIERS
The Breast. 2015;24:S51   Crossref logo
Link1 Link2

Letrozole in First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women Is Superior to Tamoxifen
Clinical Breast Cancer. 2001;1(4):272-273   Crossref logo
Link1 Link2

Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Cancer Management and Research. 2016;Volume 8:127-128   Crossref logo
Link1 Link2

Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Cancer Management and Research. 2016;Volume 8:85-94   Crossref logo
Link1

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.